III. Mechanism

IV. Dosing

  1. Adult
    1. Removed from U.S. market in 2020 due to NDMA contaminant (see adverse effects below)
    2. Bolus IV Dosing: 50 mg IV every 6 to 8 hours
    3. Continuous IV Dosing: 6.25 mg/hour IV
    4. Oral Dosing: 150 mg orally twice daily
  2. Child (15 mg/ml oral syrup)
    1. Removed from U.S. market in 2020 due to NDMA contaminant (see adverse effects below)
    2. Age <16 years old
      1. Dose: 5-10 mg/kg/day (max 300 mg) divided every 12 hours
    3. Adult dosing for over age 16 years old
      1. Dose: 150 mg twice daily
  3. Creatinine Clearance <50 ml/min
    1. Give at half dose

V. Efficacy

VI. Adverse Effects

  1. See H2 Blocker
  2. Ranitidine (Zantac) was removed from U.S. market in 2020 due to NDMA contaminant
    1. NDMA has been associated with several cancers
    2. NDMA was found both as a manufacturing contaminant
    3. NDMA also appears to form in vivo with Ranitidine use
      1. Resulted in the complete withdrawal of Ranitidine from U.S. market
      2. In-vivo NDMA formation does not appear to occur with other H2 Blockers
    4. FDA Recall Information
      1. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine
  3. IV Ranitidine associated adverse effects
    1. Alanine Aminotransferase (ALT) increase
      1. Associated with prolonged (>5 days), high dose IV use
    2. Bradycardia
      1. Associated with rapid IV administration

VII. Drug Interactions

  1. Antacids
    1. Take Cimetidine at least 1-2 hours before or after Antacid medications
  2. Decreases absorption of other medications
    1. Ketoconazole
    2. Itraconazole
  3. Warfarin
    1. May affect drug levels

VIII. Safety

  1. Pregnancy Category B
  2. Unknown safety in Lactation

X. References

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Ranitidine (C0034665)

Definition (CHV) a kind of antiacid drug
Definition (CHV) a kind of antiacid drug
Definition (NCI) A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.
Definition (MSH) A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.
Definition (CSP) N-2-(5-dimethylamino)methyl-2- furanylmethyl thioethyl-N'-methyl-2-nitro-1,1 -ethenediamine; cimetidine analog; H2 histamine receptor antagonist used to treat gastric ulcers.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D011899
SnomedCT 372755005, 48174005
LNC LP17253-3, MTHU005040
English Ranitidin, Ranitidine, N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, 1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-, N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, ranitidine (medication), histamine-2 receptor antagonists ranitidine, RANITIDINE, Ranitidine [Chemical/Ingredient], ranitidin, ranitidine, Ranitidine (product), Ranitidine (substance)
Swedish Ranitidin
Czech ranitidin
Finnish Ranitidiini
Russian RANITIDIN, РАНИТИДИН
Japanese ラニチジン
Croatian RANITIDIN
Polish Ranitydyna
Norwegian Ranitidin
Spanish ranitidina (producto), ranitidina (sustancia), ranitidina, Ranitidina
French Ranitidine
German Ranitidin
Italian Ranitidina
Portuguese Ranitidina

Ontology: Zantac (C0592278)

Definition (CHV) brand name of an heartburn medication
Definition (CHV) brand name of an heartburn medication
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D011899
English zantac, zantac [brand name], Zantac